Similar articles

• Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis.

  Putzki N, Kollia K, Woods S, Igwe E, Diener HC, Limmroth V. Putzki N, et al. Eur J Neurol. 2009 Mar;16(3):424-6. doi: 10.1111/j.1468-1331.2008.02519.x. Eur J Neurol. 2009. PMID: 19187261
• Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study.

  Oturai AB, Koch-Henriksen N, Petersen T, Jensen PE, Sellebjerg F, Sorensen PS. Oturai AB, et al. Eur J Neurol. 2009 Mar;16(3):420-3. doi: 10.1111/j.1468-1331.2008.02517.x. Eur J Neurol. 2009. PMID: 19364368
• [Choice of early and escalation treatment options for multiple sclerosis].

  Linker RA, Kieseier BC. Linker RA, et al. Nervenarzt. 2008 Oct;79(10):1123-4,1126-8,1130-2 passim. doi: 10.1007/s00115-008-2521-3. Nervenarzt. 2008. PMID: 18806985 Review. German.
• [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].

  Multiple Sklerose Therapie Konsensus Gruppe (MSTKG); Rieckmann P. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG), et al. Nervenarzt. 2006 Dec;77(12):1506-18. doi: 10.1007/s00115-006-2220-x. Nervenarzt. 2006. PMID: 17136556 German.
• Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.

  Hersh CM, Cohen JA. Hersh CM, et al. Immunotherapy. 2014;6(3):249-59. doi: 10.2217/imt.14.7. Immunotherapy. 2014. PMID: 24762071 Review.